The discovery of special CD8+ T-cell responses induced by CMV-based vectors shed light to novel prophylactic and therapeutic vaccine development, especially to pathogens that are capable of escaping host natural immunity and establishing repeated infection or chronic infection [48]. This evidence concerns the gene CD8A and infection.